Characterizing the Inflammatory Microenvironment in K14-HPV16 Transgenic Mice: Mast Cell Infiltration and MicroRNA Expression
Authors:
- Alexandra C. CostaACAlexandra C. Costa
- Joana M. O. SantosJoana M. O. Santos
- Beatriz Medeiros-FonsecaBMBeatriz Medeiros-Fonseca
- Paula A. OliveiraPaula A. Oliveira
- Margarida M. S. M. BastosMBMargarida M. S. M. Bastos
- Haissa O. BritoHaissa O. Brito
- Rui M. Gil da CostaRui M. Gil da Costa
- Rui MedeirosRui Medeiros
Open Access
Abstract
High-risk human papillomavirus (HPV) is the etiologic agent of several types of cancer. Mast cells’ role as either a driving or opposing force for cancer progression remains controversial. MicroRNAs are dysregulated in several HPV-induced cancers, and can influence mast cell biology. The aim of this study was to evaluate mast cell infiltration and to identify microRNAs potentially regulating this process. Transgenic male mice (K14-HPV16; HPV+) and matched wild-type mice (HPV−) received 7,12-Dimethylbenz[a]anthracene (DMBA) (or vehicle) over 17 weeks. Following euthanasia, chest skin and ear tissue samples were collected. Mast cell infiltration was evaluated by immunohistochemistry. MicroRNAs associated with mast cell infiltration were identified using bioinformatic tools. MicroRNA and mRNA relative expression was evaluated by RT-qPCR. Immunohistochemistry showed increased mast cell infiltration in HPV+ mice (p < 0.001). DMBA did not have any statistically significant influence on this distribution. Ear tissue of HPV+ mice showed increased mast cell infiltration (p < 0.01) when compared with chest skin samples. Additionally, reduced relative expression of miR-125b-5p (p = 0.008, 2−ΔΔCt = 2.09) and miR-223-3p (p = 0.013, 2−ΔΔCt = 4.42) seems to be associated with mast cell infiltration and increased expression of target gene Cxcl10. These results indicate that HPV16 may increase mast cell infiltration by down-regulating miR-223-3p and miR-125b-5p.Keywords
Funding Information
- Portuguese League Against Cancer—Regional Nucleus of the North (Liga Portuguesa Contra o Cancro—Núcleo Regional do Norte) (PI86-CI-IPOP-66-2017, LA/P/0045/2020, UIDB/00511/2020, UIDP/00511/2020, UID/AGR/04033/2020, 2SMART (NORTE-01-0145-FEDER-000054), SFRH/BD/135871/2018)
- Portuguese Oncology Institute of Porto (PI86-CI-IPOP-66-2017, LA/P/0045/2020, UIDB/00511/2020, UIDP/00511/2020, UID/AGR/04033/2020, 2SMART (NORTE-01-0145-FEDER-000054), SFRH/BD/135871/2018)
- Fundação para a Ciência e a Tecnologia (PI86-CI-IPOP-66-2017, LA/P/0045/2020, UIDB/00511/2020, UIDP/00511/2020, UID/AGR/04033/2020, 2SMART (NORTE-01-0145-FEDER-000054), SFRH/BD/135871/2018)
- Fundação para a Ciência e a Tecnologia (PI86-CI-IPOP-66-2017, LA/P/0045/2020, UIDB/00511/2020, UIDP/00511/2020, UID/AGR/04033/2020, 2SMART (NORTE-01-0145-FEDER-000054), SFRH/BD/135871/2018)
- FCT/MCTES (PIDDAC) (PI86-CI-IPOP-66-2017, LA/P/0045/2020, UIDB/00511/2020, UIDP/00511/2020, UID/AGR/04033/2020, 2SMART (NORTE-01-0145-FEDER-000054), SFRH/BD/135871/2018)
- Fundação para a Ciência e a Tecnologia (PI86-CI-IPOP-66-2017, LA/P/0045/2020, UIDB/00511/2020, UIDP/00511/2020, UID/AGR/04033/2020, 2SMART (NORTE-01-0145-FEDER-000054), SFRH/BD/135871/2018)
- Norte Portugal Regional Operational Programme (NORTE 2020) (PI86-CI-IPOP-66-2017, LA/P/0045/2020, UIDB/00511/2020, UIDP/00511/2020, UID/AGR/04033/2020, 2SMART (NORTE-01-0145-FEDER-000054), SFRH/BD/135871/2018)
- Fundação para a Ciência e a Tecnologia (PI86-CI-IPOP-66-2017, LA/P/0045/2020, UIDB/00511/2020, UIDP/00511/2020, UID/AGR/04033/2020, 2SMART (NORTE-01-0145-FEDER-000054), SFRH/BD/135871/2018)
- European Social Funds (FSE) (PI86-CI-IPOP-66-2017, LA/P/0045/2020, UIDB/00511/2020, UIDP/00511/2020, UID/AGR/04033/2020, 2SMART (NORTE-01-0145-FEDER-000054), SFRH/BD/135871/2018)
- National Funds of MCTES (PI86-CI-IPOP-66-2017, LA/P/0045/2020, UIDB/00511/2020, UIDP/00511/2020, UID/AGR/04033/2020, 2SMART (NORTE-01-0145-FEDER-000054), SFRH/BD/135871/2018)
This publication has 73 references indexed in Scilit:
- miRmap web: comprehensive microRNA target prediction onlineNucleic Acids Research, 2013
- Dysregulation of MicroRNAs in cancerJournal of Biomedical Science, 2012
- miRmap: Comprehensive prediction of microRNA target repression strengthNucleic Acids Research, 2012
- The role of miRNAs in human papilloma virus (HPV)-associated cancers: bridging between HPV-related head and neck cancer and cervical cancerBritish Journal of Cancer, 2012
- Conserved Regulation of p53 Network Dosage by MicroRNA–125b Occurs through Evolving miRNA–Target Gene PairsPLOS Genetics, 2011
- Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunityExperimental Biology and Medicine, 2011
- miRTarBase: a database curates experimentally validated microRNA–target interactionsNucleic Acids Research, 2010
- MicroRNA-125b is a novel negative regulator of p53Genes & Development, 2009
- Most mammalian mRNAs are conserved targets of microRNAsGenome Research, 2008
- Identification of a Dynein Interacting Domain in the Papillomavirus Minor Capsid Protein L2Journal of Virology, 2006